Clinical Data Inc

Clinical Data — Merrill Lynch Conference 2007

13 slides from Clinical Data's conference presentation, Feb 8, 2007

  1. Slide 1: Clinical Data, Inc. Merrill Lynch Conference

    Clinical Data, Inc. (r) Merrill Lynch Conference February 8, 2007

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 This presentation contains certain forward-looking information about Clinical Data that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Se

  3. Slide 3: Corporate Mission

    Corporate Mission PGxHealth is dedicated to bringing the value of pharmacogenetic testing into mainstream clinical care to benefit providers, payers and patients.

  4. Slide 4: The Clinical Data Opportunity

    The Clinical Data Opportunity Rapidly Growing Market: Market for molecular diagnostics estimated to grow from $1 Billion per annum today to $5 Billion per annum in 2010 Therapeutic Markets: Drug / Dx combination test examples in market include: Herceptin, 2006 U.S. drug sales = $1.23 b; Gleevec, 200

  5. Slide 5: Corporate Snapshot

    Corporate Snapshot NASDAQ: CLDA Market Cap: ~$183 million Annualized Revenues of $85.0 million+ (on pro forma basis) Approximately 400 employees (190 in Genomics Divisions) International presence US, UK, France, Netherlands & Italy GLP, GMP, CLIA, FDA, ISO 9001, EN13485, CE

  6. Slide 6: Divisional Structure

    Divisional Structure Vilazodone Phase III SSRI/5HT1A

  7. Slide 7: Division Focus

    Division Focus PGxHealth (Proprietary Pharmacogenetic Testing) Advance intellectual property and genetic marker development Release four to five new or enhanced tests per year Drive adoption and reimbursement through partnerships with insurers, PBM's and other key players in healthcare delivery Incr

  8. Slide 8: Division Focus

    Division Focus Grow revenue and make profitable as standalone division (cash neutral in December 2006) Introduce cutting-edge, higher margin products to market (research pain chip, LQT for clinical trials) Employ new age technology to reduce costs, increase capacity and add new products Utilize tech

  9. Slide 9: PGxHealth Tests - Sizing The US Market

    PGxHealth Tests - Sizing The US Market (4) Prevalence & Penetration rates exclude International markets Notes: (1) Initial individual test (2) "Family" test once mutation is identified (3) Estimated price only Test (1) Retail Price / Test Familion 5,400 $ Cardiovascular Long Q/T 900 ~100,000 (U.S.)

  10. Slide 10: PGxHealth Product Portfolio

    PGxHealth Product Portfolio Pharmacogenetic Test Pipeline Examples Test Therapy/Pathology Therapeutic Area Drug Metabolizing Enzymes Various (CYP for Specific Drug Metabolism) Various (CNS, GI, Oncology) UGT1A1 Irinotecan (Camptosar(r)) Oncology Schizophrenia Therapies Typical & Atypical Antipsychot

  11. Slide 11: Financial Performance

    Financial Performance Fiscal Q2 (September 30, 2006) Q4 2006 Q1 2007 Q2 2007 During last three quarters Clinical Data advances toward break-even Excluding the impact of Q2 restructuring and severance charges ($1.4M) from recent acquisitions Clinical Data approaches break-even

  12. Slide 12: Key Achievements & Milestones

    Key Achievements & Milestones Built seasoned management team Improved cash burn significantly Q-over-Q Vilazodone Phase III trial results expected Q3 2007 Demonstrated substantial growth in revenue from existing pharmacogenetic test LQT test revenue on track to more than double YOY Announced launch

  13. Slide 13: Corporate Overview July 14, 2006

    Corporate Overview July 14, 2006 Clinical Data, Inc. (r) Clinical Data, Inc. (r)

Clinical Data — Merrill Lynch Conference 2007 on 6ix